Drug Type TCR therapy |
Synonyms- |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), IL-12 stimulants(Interleukin-12 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Refuge Biotechnologies, Inc.Startup |
Active Organization Refuge Biotechnologies, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | US | Refuge Biotechnologies, Inc.Startup | 28 Feb 2023 |